Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, 3000 Leuven, Belgium.
Int J Mol Sci. 2020 Sep 7;21(18):6534. doi: 10.3390/ijms21186534.
Connexins are goal keepers of tissue homeostasis, including in the liver. As a result, they are frequently involved in disease. The current study was set up to investigate the effects of cholestatic disease on the production of connexin26, connexin32 and connexin43 in the liver. For this purpose, bile duct ligation, a well-known trigger of cholestatic liver injury, was applied to mice. In parallel, human hepatoma HepaRG cell cultures were exposed to cholestatic drugs and bile acids. Samples from both the in vivo and in vitro settings were subsequently subjected to assessment of mRNA and protein quantities as well as to in situ immunostaining. While the outcome of cholestasis on connexin26 and connexin43 varied among experimental settings, a more generalized repressing effect was seen for connexin32. This has also been observed in many other liver pathologies and could suggest a role for connexin32 as a robust biomarker of liver disease and toxicity.
连接蛋白是组织稳态的守门员,包括在肝脏中。因此,它们经常参与疾病。本研究旨在调查胆汁淤积性疾病对肝脏中连接蛋白 26、连接蛋白 32 和连接蛋白 43 产生的影响。为此,应用胆管结扎术(一种众所周知的胆汁淤积性肝损伤触发因素)对小鼠进行处理。同时,将人肝癌 HepaRG 细胞培养物暴露于胆汁淤积性药物和胆汁酸中。随后对来自体内和体外环境的样本进行 mRNA 和蛋白质定量以及原位免疫染色评估。虽然胆汁淤积对连接蛋白 26 和连接蛋白 43 的影响在实验环境中有所不同,但连接蛋白 32 则表现出更普遍的抑制作用。这种情况在许多其他肝脏病理中也有观察到,这可能表明连接蛋白 32 作为肝脏疾病和毒性的稳健生物标志物的作用。